Cost-Effectiveness of Multiple Sclerosis Disease-Modifying Therapies: A Systematic Review of the Literature. (6th December 2012)

• Record Type: Journal Article
• Authors: Yamamoto, David; Campbell, Jonathan D.
• Other Names: Savettieri Giovanni Academic Editor.
• Is Part Of: Autoimmune diseases. Volume 2012(2012)
• Publication Date: 2012-12-06
• Subjects: Autoimmune diseases -- Periodicals; 571.97305
• DOI: 10.1155/2012/784364
• Languages: English
• ISSNs: 2090-0422

Abstract

Abstract : Objective . To provide a current and comprehensive understanding of the cost-effectiveness of DMTs for the treatment of MS by quantitatively evaluating the quality of recent cost-effectiveness studies and exploring how the field has progressed from past recommendations. Methods . We assessed the quality of studies that met our systematic literature search criteria using the Quality of Health Economic Studies validated instrument. Results . Of the 82 studies that met our initial search criteria, we included 22 in this review. Four studies (18%) achieved quality category 2, three studies (14%) achieved quality category 3, and 15 studies (68%) achieved the highest quality category 4. 91% of studies were simulation models. 13 studies (59%) had quality-adjusted life years (QALYs) as the primary outcome measure, included a societal perspective in the analysis, and utilized time horizons of 10 years to lifetime. Conclusions . To continue to improve the cost-effectiveness evidence of DMTs, we recommend: lifetime horizons, societal perspectives, and QALYs; supplemental evidence with shorter horizons, payer perspectives, and clinical outcomes to inform multiple decision makers; development of modeling and input standards for comparability; head-to-head RCTs between DMTs and long-term prospective studies; and comprehensive cost-effectiveness studies that compare all appropriate DMTs.